Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Sarcoma 1Neuroblastoma 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 9Filgrastim 7Specimen Handling 6X-Rays 5Rituximab 5Radiotherapy 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Psychiatric Rehabilitation 4Nuclear Medicine Department, Hospital 4Methotrexate 4Etoposide 4Cyclophosphamide 4Biopsy 4etoposide phosphate 3Pemetrexed 3Melphalan 3Cytarabine 3Carboplatin 3tazemetostat 2sargramostim 2olaparib 2larotrectinib 2erdafitinib 2ensartinib 2Vincristine 2Vemurafenib 2Topotecan 2Thiotepa 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × Fenofibrate × Lymphoid × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡